China NMPA Product Recall - ADVIA XPT Fully Automated Biochemical Analyzer
Discuss this record with AI
Siemens Medical Diagnostics Products (Shanghai) Co., Ltd. initiated a Level III voluntary recall for its ADVIA XPT Fully Automated Biochemical Analyzer, as reported to the National Medical Products Administration (NMPA) on July 26, 2016, and publicly announced on September 30, 2016. The recall stems from a software defect in the Project Definition Software (TDef) version 1.0, specifically an erroneous ratio equation within certain CD-ROMs. This flaw impacts the accuracy of HbA1c test results when using the system's automatic pretreatment function and reporting in IFCC units (HbA1cR). The error leads to significantly decreased HbA1cR values, with reported reductions averaging 18% and a maximum of 62%, potentially compromising patient diagnosis. As corrective actions, Siemens instructed affected customers to immediately cease reporting HbA1cR results obtained via automatic pretreatment. The company committed to dispatching application personnel to perform on-site corrections of the system's ratio equation. Furthermore, Siemens will contact all customers to replace the affected TDef discs, irrespective of whether the specific automatic pretreatment function for HbA1c was actively utilized. This recall, affecting 19 units sold in China, underscores the manufacturer's responsibility under NMPA regulations to address product deficiencies impacting diagnostic reliability.
ID · a0b13b4d-3238-4b5c-be52-9649e12f3662